biomarkers
Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers
Publication year: 2012Source:Journal of Affective Disorders, Volume 137, Issues 1–3Izabela Guimarães Barbosa, Natalia Pessoa Rocha, Rodrigo Barreto Huguet, Rodrigo A. Ferreira, João Vinícius Salgado, Livia A. Carvalho, Carmine M. Pariante, Antônio Lúcio Teixeira
Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease
Objective:
DNA damage accumulation in brain is associated with the development of Alzheimer disease (AD), but newly identified protein markers of DNA damage have not been evaluated in the diagnosis of AD and other forms of dementia.
Methods:
Here, we analyzed the level of novel biomarkers of DNA damage and telomere dysfunction (chitinase activity, N-acetyl-glucosaminidase activity, stathmin, and EF-1α) in CSF of 94 patients with AD, 41 patients with non-AD dementia, and 40 control patients without dementia.
Age and diagnostic performance of Alzheimer disease CSF biomarkers
Objectives:
Core CSF changes in Alzheimer disease (AD) are decreased amyloid β1–42, increased total tau, and increased phospho-tau, probably indicating amyloid plaque accumulation, axonal degeneration, and tangle pathology, respectively. These biomarkers identify AD already at the predementia stage, but their diagnostic performance might be affected by age-dependent increase of AD-type brain pathology in cognitively unaffected elderly.
Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers
Publication year: 2012Source: Journal of Affective Disorders, Available online 16 January 2012Izabela Guimarães Barbosa, Natalia Pessoa Rocha, Rodrigo Barreto Huguet, Rodrigo A. Ferreira, João Vinícius Salgado, ...
In Search of Psychosis Biomarkers in High-risk Populations: Is the Mismatch Negativity the One We've Been Waiting for?
In this issue of Biological Psychiatry, Atkinson et al. () describe alterations in early preattentive brain electrical activity in individuals meeting criteria for ultrahigh risk (UHR) for the development of psychosis. Identifying biological markers in high-risk populations is a critical step toward informing about the pathophysiology of the disorder, predicting onset of psychosis, and potentially devising early interventions to change the course of the illness. The auditory mismatch negativity (MMN) described by Atkinson et al.
Evidence for Ordering of Alzheimer Disease Biomarkers [Original Contribution]
Objective To empirically assess the concept that Alzheimer disease (AD) biomarkers significantly depart from normality in a temporally ordered manner.
Design Validation sample.
Setting Multisite, referral centers.
Effects of Moderate-Dose Treatment With Varenicline on Neurobiological and Cognitive Biomarkers in Smokers and Nonsmokers With Schizophrenia or Schizoaffective Disorder [Original Article]
Context The administration of nicotine transiently improves many neurobiological and cognitive functions in schizophrenia and schizoaffective disorder. It is not yet clear which nicotinic acetylcholine receptor (nAChR) subtype or subtypes are responsible for these seemingly pervasive nicotinic effects in schizophrenia and schizoaffective disorder.